Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab

Abstract

CD). Notably, because of its unique mechanism of inhibiting the migration of immunocompetent cells to the intestinal tract, it has a favorable safety profile and the risk of opportunistic infections is low. 1,2 Real-world data has also reported the safety of VDZ, with the lowest risk of opportunistic infections when it is used as a single agent. 3 Although there are few reports on direct comparison with other advanced therapies, alternative network meta-analyses have shown that VDZ has the highest safety profile (especially for UC). 4,5 An elective switch from anti-tumor necrosis factor (TNF) agents to VDZ due to reasons